Hims & Hers Health (NYSE:HIMS) Stock Rating Upgraded by Citigroup

Hims & Hers Health (NYSE:HIMS) was upgraded by Citigroup from a “sell” rating to a “neutral” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has a $24.00 price objective on the stock, up from their prior price objective of $13.25. Citigroup’s price objective points to a potential downside of 7.29% from the stock’s current price.

HIMS has been the topic of a number of other reports. Evercore set a $24.00 target price on Hims & Hers Health in a research note on Tuesday, February 24th. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, TD Cowen reduced their target price on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.75.

Hims & Hers Health Stock Up 10.3%

NYSE:HIMS opened at $25.89 on Tuesday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The stock has a 50 day moving average of $24.18 and a 200-day moving average of $37.66. The firm has a market capitalization of $5.90 billion, a PE ratio of 50.76, a price-to-earnings-growth ratio of 4.55 and a beta of 2.55. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted $0.11 EPS. Analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share buyback program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to buy up to 3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. This represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 80,463 shares of company stock valued at $2,846,696. Company insiders own 13.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently made changes to their positions in HIMS. Pathway Capital Management LP bought a new stake in Hims & Hers Health during the third quarter worth approximately $6,766,000. Steadview Capital Management LLC increased its holdings in shares of Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock valued at $39,809,000 after buying an additional 311,845 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Hims & Hers Health by 49.2% during the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after acquiring an additional 678,600 shares during the last quarter. Carnegie Investment Counsel lifted its position in shares of Hims & Hers Health by 25.4% during the 3rd quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock valued at $17,238,000 after acquiring an additional 61,560 shares during the last quarter. Finally, BIT Capital GmbH boosted its stake in shares of Hims & Hers Health by 73.8% during the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after acquiring an additional 938,728 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.